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Objective: This study aims to describe the prevalence of health care utilisation (including 
conventional medicine, self-care and complementary medicine treatments) for the 
management of asthma by women aged 45 years and over and their associated out-of-pocket 
expenditure. Methods: A self-reported mail survey of 375 Australian women, a cohort of the 
national 45 and Up Study, reporting a clinical diagnosis of asthma. The women were asked 
about their use of health care resources including conventional medicine, complementary 
medicine, and self-prescribed treatments for asthma and their associated out-of-pocket 
spending. Spearman’s correlation coefficient, student’s t-test and chi-square test were used as 
appropriate. Population level costs were created by extrapolating the costs reported by 
participants by available national prevalence data. Results: Survey respondents (N=375; 
response rate, 46.9%) were, on average, 67.0 years old (min 53, max 91). The majority 
(69.1%; n=259) consulted at least one health care practitioner in the previous 12 months for 
their asthma. Most of the participants (n= 247; 65.9%) reported using at least one prescription 
medication for asthma in the previous 12 months. The total out-of-pocket expenditure on 
asthma treatment for Australian women aged 50 years and over is estimated to be AU$159 
million per annum. Conclusions: The breadth of conventional and complementary medicine 
health care services reported in this study, as well as the range of treatments that patients self-







Asthma is a chronic respiratory disorder characterised by periodic episodes of (mostly) 
reversible airway obstruction and subsequent wheezing, shortness of breath, cough and/or 
chest tightness (1). In 2015, 358.2 million individuals worldwide were affected by asthma (2) 
(a prevalence constituting an increase of 12.6% since 1990), which is projected to rise to 400 
million cases by 2025 (3). The highest rate of doctor-diagnosed asthma is reported in 
Australia, with a prevalence rate of 21%, compared with 4.3% globally (4). Although the 
prevalence of asthma among Australians aged 45 years and over is 10.3% (5), this rate is still 
more than double the global prevalence.  
 
There is considerable burden associated with asthma. The global burden of disease study 
reported that 26.2 million disability-adjusted life years were attributed to asthma in 2015, 
which represents 1.1% of total disease burden worldwide (2). The financial burden associated 
with asthma is also high, including direct health care expenditure and costs attributed to 
absenteeism and mortality. In the United States (US), the total cost of asthma was estimated 
at US$81.9 billion in 2013 (6), and in Australia at AU$27.9 billion in 2015 (7).  
 
As there is no cure for asthma, most clinical guidelines tend to focus on the maintenance of 
good symptomatic control as the primary goal of asthma management (8, 9). In conventional 
medicine, treatment primarily focuses on risk minimisation (e.g. reducing exposure to known 
risk factors) and pharmacological management. Using a stepwise approach, an individual’s 
treatment will vary depending on the severity of symptoms; ranging from the use of short 
acting beta agonists for mild, intermittent and persistent asthma, to the use of inhaled/oral 
corticosteroids and/or long acting beta agonists for more severe and persistent asthma (8-10). 
More recently, monoclonal antibody-based biologics have been shown to be effective for 
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managing asthma that is unresponsive to other treatments (11). While most available asthma 
treatments are reported to be effective in controlling asthma symptoms (based on the findings 
of high quality systematic reviews), long-term safety data and evidence of efficacy in adults 
aged 45 years and over is lacking (11). In the absence of strong clinical data, effective asthma 
management in adults aged 45 years and over relies heavily on coordinated, person-centred 
care to ensure patients are receiving safe and appropriate clinical management (12).  
 
In addition to evidence gaps regarding effective asthma treatments for adults aged 45 years 
and over, adherence to prescribed treatments also poses a challenge to the effective 
management of the condition (13). Data from a qualitative investigation of 25 Australian 
patients with severe asthma identified side effects, perceived low efficacy and cost of asthma 
treatment as key drivers of low adherence to asthma treatment (14). Consistent with this 
finding, other Australian research focusing on adults in their 60s found perceived or 
experienced side effects from asthma medication to be particularly influential in treatment 
adherence for this population (12). These same factors may also explain why some people 
seek other treatment options to improve their asthma symptoms, such as complementary 
medicine (CM) (15, 16).  
 
Based on the findings of a systematic review of 72 international studies, the prevalence of 
CM use among individuals with asthma may be as high 100% in adults (17), with level of use 
directly related to the severity of the asthma (18). The therapies most frequently used were 
found to be CM products (comprising herbal medicines and nutritional supplements) and 
mind-body techniques (including meditation, tai chi and yoga). For most of these treatments, 
evidence of efficacy is either insufficient or absent (17, 19, 20). However, some treatments 
including massage therapy (20), the Buteyko breathing technique (21) and Boswellia serrata 
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(22) do show promise in improving outcomes such as lung function and bronchodilator use. 
Notwithstanding, it is unclear to what extent individuals with asthma use these potentially 
more promising CM treatments over less evidence-based CM treatments, and whether 
individuals use CM in conjunction with, or as a replacement for, conventional medicine or 
self-care treatments.  
 
In response to this knowledge gap, we present the findings from the first known study to 
report on the prevalence of health care utilisation (including conventional medicine, self-care 
and complementary medicine treatments) and associated out-of-pocket expenditure for the 




This study aims to describe the prevalence of health care utilization and associated out-of-
pocket expenditure for the management of asthma in women aged 45 years and over. It also 
aims to examine any associations between the time since diagnosis and self-reported asthma 
severity with consultation rates, prescription medicine use, complementary medicine product 
and practice use, and out-of-pocket expenses.   
 
Design 





The 45 and Up Study is the largest study of healthy ageing conducted in the Southern 
Hemisphere. The 45 and Up Study is described in detail elsewhere (23); but is briefly 
outlined below.  
 
Sample  
Men and women residing in New South Wales, Australia and aged 45 years and above were 
randomly selected from the Medicare Australia database––a government-administered 
database that provides virtually complete coverage of the general population––and invited to 
participate in the 45 and Up Study. Participants (N=266,848) entered the study by completing 
a baseline postal questionnaire and providing written consent to have their health followed 
over time. For the ancillary study reported here, 800 women who indicated that they had been 
diagnosed as having asthma by a doctor were mailed a questionnaire between August and 




The participants were asked a number of questions regarding demographic characteristics, 
including their: date of birth, highest completed educational qualification, marital status, 
whether they had private health insurance, and their ability to manage on their income (i.e. no 
or little difficulty, some difficulties, struggled). In addition, area of residence was assigned 
according to the Accessibility Remoteness Index of Australia Plus score for each 
participant’s postcode (i.e. major city, inner regional area, outer regional or remote area) 
(Australian Institute of Health and Welfare 2004).  
 
Health care utilisation 
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The women were asked to indicate (yes/no) if they consulted any of the following health care 
practitioners for their asthma in the previous 12 months: conventional medical practitioners 
(including general practitioner, medical specialist, hospital doctor); allied health practitioners 
(including nurse, pharmacist/chemist, counsellor, psychologist, dietitian, physiotherapist, 
occupational therapist); and CM practitioners (including acupuncturist, chiropractor, 
naturopath/herbalist, homeopath, massage therapist, meditation instructor, yoga instructor, 
nutritionist, osteopath, traditional Chinese medicine practitioner, and an ‘other’ CM 
practitioner option). Participants were also asked how many times they consulted each 
practitioner type in the previous 12 months (i.e. 1 or 2, 3 - 6, or 7 or more). 
 
The women were further provided with a list of CM products/practices (i.e. aromatherapy 
oils, herbal medicines, multivitamins, cod liver oil, fish oil, homeopathic remedies, 
meditation without an instructor, yoga without an instructor, physical activities/exercises, and 
two open-text options for participants to list ‘other’ CM products/practices options) and 
asked if they used any of these during the previous 12 months. There were three response 
options: At least once daily, At least weekly, and At least monthly. In addition, the women 
were asked to list (open text response) any prescription medications they had used for their 
asthma during the previous 12 months.  
 
With regard to the above health care options for asthma, the women were asked to indicate  
the total expenditure (i.e. out-of-pocket costs) attributed to medical/allied health practitioner 
consultations, CM practitioner consultations, CM product and practice purchases, and 
prescription medication use, over the 12-month period. There were five response options for 
each type of expense (1 = Up to $100, 2 = $100 - $499, 3 = $500 - $999, 4 = $1,000 – 





The women were asked to rate the severity of their asthma during the previous 12 months, on 
a 10-point scale ranging from 0 (least severe) to 10 (most severe). The women were also 
asked to specify the time (years/months) since they were first diagnosed with asthma.  
 
Statistical analyses 
Due to the data being non-normally distributed, Spearman’s correlation coefficients were 
used to examine the association between two continuous variables (e.g. determine the 
correlation between the 12-month and 4-week self-rated severity of asthma). Student’s t-tests 
were used to make comparisons between continuous and categorical variables (e.g. average 
number of consultations or average cost vs years since diagnosis or severity of asthma). 
When the data were considered non-normally distributed, two-sample Wilcoxon rank-sum 
tests were used to make comparisons between continuous and categorical variables (e.g. to 
compare the difference in costs between years since diagnosis or severity of asthma). Chi-
square tests were used to examine the association between two categorical variables (e.g. use 
of prescription medicines or complementary medicine products and practices vs years since 
diagnosis or severity of asthma). The financial costings of population level out-of-pocket 
direct health care expenditure were based on 2016 Australian population census figures for 
women aged 50 years and over (n=4,165,907) (24) and asthma prevalence data as reported by 
the Australian Institute of Health and Welfare (10.8%; 449,918) (5, 24). These figures were 
then extrapolated from the average individual out-of-pocket expenditure identified through 
calculation of the mean. All costings were reported in Australian dollars. All analyses were 





The University of NSW Human Research Ethics Committee approved the baseline 45 and Up 
study and the ancillary study reported on in this paper. The University of Technology Sydney 
Human Research Ethics Committee also approved the sub-study in accordance with the 




The survey was returned by 375 women (response rate = 46.9%). The average age of the 
women was 67.0 (SD=8.8) years, with a minimum age of 53 years and a maximum age of 91 
years. Almost half of the women (45.6%) resided in an inner regional area, 42.6% resided in 
a major city, and 11.8% resided in an outer regional or remote area. The majority of the 
women (65.1%) were married or in a de facto relationship, with 26.8% widowed, divorced or 
separated, and 8.1% single. In terms of ability to manage on available income, 68.9% had no 
or little difficulty, 20.6% had some difficulties, and 10.5% had struggles. The majority of the 
women (72.6%) had private health insurance. A university degree was attained by 34.0% of 
the women, while 33.0% gained a certificate or diploma, 26.8% a high school education, and 
6.2% had no formal education.  
 
Asthma characteristics 
In terms of self-rated severity of asthma (out of 10; with 10 being most severe), the average 
severity rating for the women was 2.8 (SD=1.9) over the past 12 months and 2.7 (SD=2.2) 
over the past 4 weeks; noting that the 12-month and 4-week self-rated severity of asthma 
were highly correlated (=0.68, p<0.001). The average time since the first clinical diagnosis 




Consultations with health care practitioners 
The majority of the women (69.1%; n=259) consulted at least one health care practitioner in 
the previous 12 months for their asthma. Specifically, 67.2% (n=252) consulted a doctor, 
20.8% (n=78) consulted an allied health practitioner, and 9.6% (n=36) consulted a CM 
practitioner. Of the women that consulted a CM practitioner, 5 consulted a CM practitioner 
only, and 31 consulted both a CM practitioner and a doctor. Of the women that consulted an 
allied health practitioner, 2 consulted an allied health practitioner only, and 76 consulted both 
an allied health practitioner and a doctor. 
 
Table 1 shows the consultations with health care practitioners by years since diagnosis of 
asthma and severity of asthma over the past 12 months. Women who rated their severity of 
asthma as being 5 or more points (out of 10) had a greater number of consultations with 
health care practitioners, specifically doctors (p<0.001) and allied health practitioners 
(p<0.001), compared to women who rated their severity of asthma as less than 5 points. 
Overall, the women had on average 3.8 consultations with health care practitioners in the 
previous 12 months specifically for their asthma.  
 
Use of prescription medications 
The use of prescription medications for asthma by years since diagnosis of asthma and 
severity of asthma over the past 12 months is presented in Table 2. Three categories of 
prescription medications were determined based on the information provided by the women: 
1) bronchodilators (such as Salbutamol, Vilanterol and Formoterol); 2) inhaled or systemic 
steroidal anti-inflammatory drugs (such as Budesonide and Prednisone); and 3) ‘other’ 
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prescription medications (including antibiotics [such as Amoxycillin] and leukotriene 
receptor antagonist drugs [such as Montelukast]).  
 
The majority of the participants (n=247; 65.9%) reported using at least one type of 
prescription medication for asthma in the previous 12 months. A greater percentage of 
women who rated their severity of asthma as being 5 or more points (out of 10) used 
bronchodilators (83.6%) (p<0.001, χ2=12.657), steroidal anti-inflammatory drugs (59.0%)  
(p=0.004, χ2=8.251), and/or other prescription medications (14.8%) (p<0.001, χ2=13.737), 
compared to women who rated their severity of asthma as being less than 5 points (59.6%, 
34.5%, and 3.3% respectively). There were no statistically significant associations between 
use of any prescription medication and years since diagnosis. 
 
Use of CM products and practices 
Table 3 shows the use of CM products and practices by years since diagnosis of asthma and 
severity of asthma over the past 12 months. There was no statistically significant associations 
between number of different CM products and practices used for asthma and years since 
diagnosis with asthma (p=0.194, χ2=4.719), nor severity of asthma (p=0.706, χ2=1.398).  
 
Out-of-pocket expenses 
The out-of-pocket expenses by years since diagnosis of asthma and severity of asthma over 
the past 12 months are presented in Table 4. Women who rated their severity of asthma as 
being 5 or more (out of 10) reported higher out-of-pocket expenditure with regards to their 
consultations with doctors and allied health practitioners (p=0.002, z=-3.098), and their use of 
prescription medications (p<0.001, z=-4.610), compared to women who rated their severity 
of asthma as being less than 5 points. There were no statistically significant differences in 
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out-of-pocket expenditure between women who had been diagnosed with asthma for less than 
10 years and those who had been diagnosed with asthma 10 or more years previously, in 
terms of expenditure on consultations with doctors or allied health practitioners, prescription 
medications, CM practitioner consultations, or CM products and practices.  
 
On average, the combined out-of-pocket expenditure for asthma-associated health care (based 
on participant self-report) was AU$354.0 per annum, per participant. Extrapolating from 
available national figures, and assuming an average individual out-of-pocket expenditure in 
line with that of the women from this study (AU$354.0), we estimate the total out-of-pocket 
expenditure on asthma treatment for Australian women aged 50 years and over to be 
approximately AU$159 million per annum. Of this total, AU$60M of expenditure can be 
attributed to prescription medications, AU$47M for consultations with doctors, AU$34M for 
CM products/practices and AU$18M for consultations with CM practitioners. 
 
DISCUSSION 
Our study provides the first analysis of both conventional and CM health care utilisation 
(including consultations with health providers as well as self-care practices and product use) 
for asthma amongst Australian women aged 53 to 91 years.  The study findings highlight the 
key role of health professionals in asthma management with over two thirds of women 
consulting with at least one health care practitioner for their asthma in the previous 12 
months. However, as under-treatment of asthma is an identified issue in Australians in their 
50s and 60s (12), the lack of engagement with a health professional for the remaining women 
in our study is an important finding that may present problems for the ongoing management 




While our data indicate that the majority of participating women consulted a doctor for their 
asthma care, a large number interacted with an allied health or CM practitioner in addition to 
their doctor. We also found that a positive association between self-rated severity of asthma 
illness and number of consultations with doctors and allied health professionals (but not CM 
practitioners). These findings contradict those of a US study, which found CM use to be 
higher among adults with more severe asthma (evidenced by emergency room visits or 
asthma-associated disability days) (18). It is possible that these contrasting findings could be 
reflective of the different health funding arrangements in the two countries. For example, 
individuals with severe asthma in Australia may prefer to access public-funded conventional 
health services over CM healthcare options in order to reduce out-of-pocket healthcare costs, 
whereas those in the US may choose to prioritise CM services/treatments for their asthma in 
an attempt to minimise out-of-pocket expenditure on conventional healthcare 
services/treatments (25, 26). This incongruence between study findings may also relate to 
differences in how asthma severity is measured.  
 
The findings of our study may allay concerns that CM users with asthma are at risk of 
missing out on appropriate care (27), instead suggesting that CM may be used by older 
women to support mild or chronic asthma symptoms while conventional treatments are 
prioritised for severe asthma episodes. Irrespective of severity, the range of health 
professionals potentially providing care to the same individual for the same condition, as 
reported in our study, emphasises the importance of effective coordination of care across all 
members of the healthcare team. Current data suggests one in five Australians aged 65 years 
and older currently experience problems with the coordination of care received between 
doctors and allied health practitioners (28). In addition, CM care currently exists outside of 
the lens of mainstream health service provision in Australia (29). Consequently, mechanisms 
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to ensure appropriate coordination of health care require urgent consideration from 
researchers and policy makers to ensure safe, effective, coordinated patient management for 
those with asthma.  
 
Our study also found more than one in three women used some form of CM product or 
practice to assist the management of their asthma. However, neither severity of illness nor 
years since diagnosis were associated with CM use in this population. Similarly, the 
proportion of women using a CM product or practice was nearly four times greater than the 
proportion of those who reported visiting a CM practitioner - suggesting that CM use was 
either self-prescribed or recommended under the direction of a medical doctor or allied health 
professional. A previous study of CM use for chronic disease (30) reported a much lower rate 
of CM use (11-12%) among adult Australian women with asthma. However, the definition of 
CM in this previous study was restricted to vitamins/minerals or herbal products only, 
whereas the definition employed in our study encompassed a much broader range of CM 
services and products.   
 
The efficacy of CM treatments for asthma is limited at best; although, some evidence 
supports the use of massage therapy (20), the Buteyko breathing technique (21) and the 
Ayurvedic herbal medicine Boswellia serrata (22). An expert review on asthma in adults aged 
between 50 and 70 years identified a number of factors affecting the applicability of the 
available evidence for this population, such as the use of restrictive RCT designs that exclude 
older patients or those with comorbidities (11) – features that may also compromise the value 
of research conducted on CM products and treatments. As such, the body of evidence for 
asthma management in older adults is insufficient for delivering evidence-based care to this 
population, whether that be using conventional medicine or CM treatments. The high rate of 
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CM use identified in our study suggests that the low evidence-base for CM did not deter 
participants from using these services/treatments to assist with asthma management. This is 
consistent with evidence from epidemiological research indicating that older adults with 
asthma tend to deviate from current recommended guidelines for asthma care (13). In 
addition, men and women in their 50s and 60s with asthma often have heightened concerns 
regarding the side-effects of pharmaceutical asthma treatments, and furthermore, are more 
likely to be non-adherent to prescribed treatment if they experience side-effects (12).  
 
On average, annual out-of-pocket expenditure for asthma-associated health care was AU$354 
per participant, which equates to approximately AU$159 million per annum for Australian 
women aged 50 years or over. While this out-of-pocket cost was directly related to women’s 
self-rated asthma severity, it was not linked to time since diagnosis. Cost of care can be a 
significant barrier to access for older people. A global survey in 11 countries found 8% of 
Australians aged 65 years or over forgo access to health care (e.g. doctor visits, medical tests, 
filling a prescription, skipping doses) due to cost (28). Contrary to previous prevalence 
studies in the general population, Australian adults with chronic disease (including asthma) 
have been found to be more likely to use CM if they are in the lower income quintiles (30). 
This aligns with US research findings that show individuals reporting financial barriers to 
asthma care were more likely to use CM (18). Given the significant subsidies to asthma 
medication and primary care in Australia and the absence of such subsidies for the majority 
of CM services, products and treatments, the impact of financial drivers for CM use in this 
population warrants closer examination.  
 
The findings from this analysis need to be interpreted with caution. While the research draws 
upon a robust and internationally-recognised study sample, the cross-sectional study design 
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does limit the ability to determine causality between variables. Second, the 45 and Up cohort 
is, by definition, restricted to a specified age range. As such, the results from this study may 
only represent women aged 45 years and older and should not be generalised to women from 
younger age groups or to men. The economic cost calculations reported in this study do not 
indicate the overall individual or societal burden of asthma nor provide comparative data on 
the cost-benefit or cost-effectiveness of different treatments. Instead our data only quantifies 
the direct financial out-of-pocket costs associated with health care and must be interpreted 
within the constraints of these boundaries. More detailed economic analyses are needed to 
provide richer context to our study findings. The severity of asthma was measured using an 
instrument that, while widely utilised in asthma research, is not a validated scale. As such, the 
internal validity of the data pertaining to asthma severity must be carefully considered. 
Finally, the survey data were collected via self-report and this may have introduced recall 
bias. Despite these limitations, this study is the first to explore health service utilisation for 
asthma in this population, and given the issues surrounding clinical evidence for asthma care 
in people aged 45 and older, may direct important future research and policy discussions on 
this topic.  
CONCLUSIONS 
Our study reports for the first time, the prevalence and estimated expenditure across all 
sectors of health care utilisation (i.e. conventional and complementary medicine practitioner 
care, and conventional medicine and CM self-care practices and products) amongst a sample 
of older women with asthma. Given the considerable expenditure on CM services/products, it 
is imperative that further work seek to establish the evidence-base of different CM treatments 
used for the management of asthma. Moreover, the breadth of health care services used 
across the conventional and complementary medicine sectors, as well as the range of 
treatments that patients self-prescribe, highlights the need for, but also the challenges of, 
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coordinating care for individuals living with asthma. At the very least, the findings allude to 
the importance of conventional, complementary and allied health care providers initiating 
conversations with their patients about the use of other medical/allied/CM interventions for 
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Table 1 Consultations with health care practitioners by years since diagnosis of asthma and 
severity of asthma over the past 12 months. 
     
   Average Number of Consultations  





   Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
       
Years Since  <10 years (n=40) 2.5 (3.1) 0.9 (3.2) 0.7 (3.2) 4.1 (6.7) 
Diagnosis ≥10 years (n=323) 2.0 (2.6) 1.1 (3.3) 0.8 (3.4) 3.8 (7.2) 
 p-value  0.246 0.733 0.897 0.835 
 t  1.162 -0.342 -0.129 0.209 
       
Severity of  <5 points (n=307) 1.5 (1.9) 0.7 (2.5) 0.7 (3.0) 2.9 (5.1) 
Asthma †  ≥5 points (n=61) 4.3 (4.2) 2.9 (5.4) 1.1 (4.9)  8.3 (12.4) 
 p-value  <0.001 <0.001 0.387 <0.001 
 t  -8.212 -4.981 -0.866 -5.641 
       
Total 
Sample 
 (n=375) 2.0(2.6) 1.0(3.2) 0.7(3.4) 3.8(7.1) 
       
 
† Self-rated severity score out of 10 (1=least severe and 10=most severe)  
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Table 2 Use of prescription medications by years since diagnosis of asthma and severity of 
asthma over the past 12 months, with figures presented being row percentages. 
 
A  bronchodilators such as Salbutamol, Vilanterol and Formoterol (included 73 women who took the combined bronchodilator 
and steroidal anti-inflammatory drug Seretide). 
 
B  steroidal anti-inflammatory drugs such as Cortisone, Symbicort and Prednisone (included 73 women who took the combined 
bronchodilator and steroidal anti-inflammatory drug Seretide). 
 
C  antibiotics such as Amoxycillin and leukotriene receptor antagonist drugs such as Singulair. 
† self-rated severity score out of 10 (1=least severe and 10=most severe) 
 
  
    









  medications C 
       Yes    Yes Yes 
   (n=235) (n=205) (n=19) 





(n=40) 60.0% 37.5% 5.0% 
Diagnosis ≥10 
years 
(n=323) 64.4% 38.4% 5.3% 
 p-value  0.585 0.557 0.944 
 2  0.298 0.345 0.005 
         
Severity of  <5 points (n=307) 59.6% 34.5% 3.3% 
Asthma † ≥5 points (n=61) 83.6% 59.0% 14.8% 
 p-value  <0.001 0.004 <0.001 
 2  12.657 8.251 13.737 
22 
 
Table 3 Use of complementary medicine products and practices by years since diagnosis of 




† Self-rated severity score out of 10 (1=least severe and 10=most severe) 
        
    Number of Different Complementary 
Medicine Products and Practices Used 
  




p-value 2  
   (n=229) (n=53) (n=31) (n=50) 
 
  




<10 years (n=40) 47.5% 20.0% 12.5% 20.0% 
0.194 4.719 
≥10 years (n=323) 65.0% 13.9% 8.1% 13.0% 
         
         
Severity of  
Asthma † 
<5 points (n=307) 63.8% 14.7% 8.8% 12.7% 
0.706 1.398 
≥5 points (n=61) 59.0% 13.1% 9.9% 18.0% 
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Table 4 Out-of-Pocket expenses by years since diagnosis of asthma and severity of asthma 
over the past 12 months. 
       
   Average Cost 

















   Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
        
Years 
Since  




















 p-value  0.468 0.526 0.938 0.919 0.627 
 z  0.726 -0.635 -0.078 0.101 0.486 
        
Severity 
of  




















 p-value  0.002 0.502 <0.001 0.129 <0.001 
 z  -3.098 -0.672 -4.610 -1.516 -3.959 
        
Total 
Sample 










        
 
† Self-rated severity score out of 10 (1=least severe and 10=most severe) 
 
